At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A D1 Agonist For Working Memory Enhancement In The Schizophrenia Spectrum
In Brief
A Phase 2 clinical trial evaluating DAR 0-100A and Placebo for Schizotypal Personality Disorder and SPD. Completed, enrolled 120 participants across 1 site.
Detailed Summary
The purpose of the study is to examine the effects of the administration of a drug called DAR-0100A on attention and memory in persons with schizotypal personality disorder (SPD). DAR-0100A has not been FDA approved, however in recent studies has been used to treat cognitive deficits, meaning problems in the way you organize your thinking, in people diagnosed with schizophrenia. Many people who carry a diagnosis of schizotypal personality disorder have trouble with attention and memory. Increasing the presence of a brain chemical called dopamine has been found to help people with schizophrenia with their attention and memory problems. This study will investigate whether the same is true for people with schizotypal personality disorder by using DAR-0100A, a drug that has been shown to help with the cognitive deficits of people with Parkinson's disease by increasing dopamine effects. Information collected in this experiment may lead to a better understanding of the brain mechanisms involved in schizotypal personality disorder and improve treatments for the psychological problems associated with this condition.
Study Details
Timeline
Interventions
15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.
15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.